{"title":"CardioSEAL和Starflex装置在房缺损封堵中的作用。","authors":"Pedra, McLaughlin, Benson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The CardioSEAL and Starflex implants (Nitinol Medical Technologies, Boston, MA) are self-expanding, double-umbrella septal occluders designed to close small to moderate secundum atrial septal defects (ASDs), the latter having a self-centering mechanism. Overall, successful clinical defect occlusion occurs in more than 90% of patients following implantation. In this article, we discuss the development, design issues, technique of implantation, and clinical results pertinent to these new devices.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":"2 3","pages":"274-282"},"PeriodicalIF":0.0000,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Role of CardioSEAL and Starflex Devices in Atrial Defect Occlusion.\",\"authors\":\"Pedra, McLaughlin, Benson\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The CardioSEAL and Starflex implants (Nitinol Medical Technologies, Boston, MA) are self-expanding, double-umbrella septal occluders designed to close small to moderate secundum atrial septal defects (ASDs), the latter having a self-centering mechanism. Overall, successful clinical defect occlusion occurs in more than 90% of patients following implantation. In this article, we discuss the development, design issues, technique of implantation, and clinical results pertinent to these new devices.</p>\",\"PeriodicalId\":80270,\"journal\":{\"name\":\"Current interventional cardiology reports\",\"volume\":\"2 3\",\"pages\":\"274-282\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current interventional cardiology reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
CardioSEAL和Starflex植入物(Nitinol Medical Technologies, Boston, MA)是一种可自我扩展的双伞状房间隔封堵器，用于关闭小至中度的二次房间隔缺损(asd)，后者具有自定心机制。总的来说，超过90%的患者在植入后成功地实现了临床缺陷闭塞。在本文中，我们将讨论这些新装置的发展、设计问题、植入技术和临床结果。
The Role of CardioSEAL and Starflex Devices in Atrial Defect Occlusion.
The CardioSEAL and Starflex implants (Nitinol Medical Technologies, Boston, MA) are self-expanding, double-umbrella septal occluders designed to close small to moderate secundum atrial septal defects (ASDs), the latter having a self-centering mechanism. Overall, successful clinical defect occlusion occurs in more than 90% of patients following implantation. In this article, we discuss the development, design issues, technique of implantation, and clinical results pertinent to these new devices.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
